ADMA BIOLOGICS, INC. (ADMA)
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law
VIA Investors Have Opportunity to Lead Via Transportation, Inc. Securities Fraud Lawsuit with SBS Law
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company
Ekstraordinære indfrielser (CK 93)
Started to be an interested party - Migdal Insurance and Financial Holdings Ltd.
Presentation to the capital market - second quarter of 2026
General Announcement: Transaction in own shares
PaysafeWallet Is Now Live in Poland: Your Money, Your Way
Financial Statements and Related Announcement: Profit Guidance
Oculis undirritar kaupsamning við Accure Therapeutics um leiðandi þróunarlyfið Privosegtor og eflir þannig stöðu Oculis sem leiðandi vaxtarfyrirtækis á sviði taugaaugnlækninga